Skip to main content
. 2016 Jun 20;34(9):1863–1871. doi: 10.1097/HJH.0000000000001025

TABLE 2.

Characteristics of antihypertensive treatment at baseline

Variable Renal denervation (n = 11) Spironolactone (n = 13)
RAS blockers, n (%) 11 (100) 12 (92)
α-blockers, n (%) 6 (55) 5 (39)
β-blockers, n (%) 6 (55) 10 (77)
Calcium-channel blockers, n (%) 10 (91) 9 (69)
Diureticsa, n (%) 11 (100) 13 (100)
Centrally acting drugs, n (%) 2 (18) 1 (8)

RAS, renin–angiotensin system.

aOther than mineralocorticoid-receptor blockers.